Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens

Hypersensitivity reactions (HSRs) to paclitaxel are frequently encountered in patients receiving this antitumour drug. Administration of histamine H1- and H2-receptor antagonists and corticosteroids has been shown to reduce significantly the risk of developing an HSR in patients receiving taxanes. I...

Descripción completa

Detalles Bibliográficos
Autores principales: Kloover, J S, Bakker, M A den, Gelderblom, H, Meerbeeck, J P van
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409560/
https://www.ncbi.nlm.nih.gov/pubmed/14974481
http://dx.doi.org/10.1038/sj.bjc.6601303
_version_ 1782155797845770240
author Kloover, J S
Bakker, M A den
Gelderblom, H
Meerbeeck, J P van
author_facet Kloover, J S
Bakker, M A den
Gelderblom, H
Meerbeeck, J P van
author_sort Kloover, J S
collection PubMed
description Hypersensitivity reactions (HSRs) to paclitaxel are frequently encountered in patients receiving this antitumour drug. Administration of histamine H1- and H2-receptor antagonists and corticosteroids has been shown to reduce significantly the risk of developing an HSR in patients receiving taxanes. In this case report, we describe the fatal outcome of an HSR in a patient receiving paclitaxel despite short-course premedication. The level of evidence supporting the short-course i.v. premedication schedule is challenged, as it is not compatible with the pharmacokinetic properties of dexamethasone.
format Text
id pubmed-2409560
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-24095602009-09-10 Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens Kloover, J S Bakker, M A den Gelderblom, H Meerbeeck, J P van Br J Cancer Short Communication Hypersensitivity reactions (HSRs) to paclitaxel are frequently encountered in patients receiving this antitumour drug. Administration of histamine H1- and H2-receptor antagonists and corticosteroids has been shown to reduce significantly the risk of developing an HSR in patients receiving taxanes. In this case report, we describe the fatal outcome of an HSR in a patient receiving paclitaxel despite short-course premedication. The level of evidence supporting the short-course i.v. premedication schedule is challenged, as it is not compatible with the pharmacokinetic properties of dexamethasone. Nature Publishing Group 2004-01-26 2004-01-20 /pmc/articles/PMC2409560/ /pubmed/14974481 http://dx.doi.org/10.1038/sj.bjc.6601303 Text en Copyright © 2004 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Short Communication
Kloover, J S
Bakker, M A den
Gelderblom, H
Meerbeeck, J P van
Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens
title Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens
title_full Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens
title_fullStr Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens
title_full_unstemmed Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens
title_short Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens
title_sort fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409560/
https://www.ncbi.nlm.nih.gov/pubmed/14974481
http://dx.doi.org/10.1038/sj.bjc.6601303
work_keys_str_mv AT klooverjs fataloutcomeofahypersensitivityreactiontopaclitaxelacriticalreviewofpremedicationregimens
AT bakkermaden fataloutcomeofahypersensitivityreactiontopaclitaxelacriticalreviewofpremedicationregimens
AT gelderblomh fataloutcomeofahypersensitivityreactiontopaclitaxelacriticalreviewofpremedicationregimens
AT meerbeeckjpvan fataloutcomeofahypersensitivityreactiontopaclitaxelacriticalreviewofpremedicationregimens

Ejemplares similares